NRx Pharmaceuticals, Inc. announced the date for its 2025 Annual Meeting and the record date for stockholders.
The annual meeting is scheduled to be held on March 23, 2026, in a virtual-only format.
Stockholders of record as of February 12, 2026, will be entitled to notice of and vote at the 2025 Annual Meeting.
Annual Meeting Details
The 2025 Annual Meeting will take place on March 23, 2026, in a virtual-only format.
Record Date
Stockholders as of February 12, 2026, will have voting rights at the annual meeting.
Proposal Submission Deadline
Stockholder proposals or nominations must be submitted by January 26, 2026, in accordance with the Bylaws.
Therapeutics Development
NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders based on its NMDA platform.
- The announcement provides clarity to stockholders regarding the upcoming meeting and voting rights.
- Stockholders now have a clear deadline for submitting proposals or nominations for consideration at the 2025 Annual Meeting.
NRx Pharmaceuticals is gearing up for its 2025 Annual Meeting, offering stockholders the opportunity to participate in key decisions. The company's focus on developing therapeutics for CNS disorders underscores its commitment to addressing critical medical needs.